Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenic disorders (1:400-1000) and an important cause of end stage renal disease (ESRD). In the US in 2012, ~30,000 patients had PKD associated ESRD;1/3500 individuals aged 65-69y. The disease is generally late in onset, but considerable variability exists, from in utero onset and perinatal death, early onset (EO) disease, to adequate renal function into old age. Extrarenal manifestations, particularly a higher incidence of intracranial aneurysms (ICA) and severe polycystic liver disease (sPLD) are associated with morbidity and mortality. The overall goal of this proposal is to determine the extent to which genetic factors at the two known genes, PKD1 (16p13.3) and PKD2 (4q21) and elsewhere in the genome, determine the severity of renal disease and the occurrence of clinically significant extrarenal complications. These studies are based upon our findings, and those of others that genic, allelic and genetic background effects significantly influence the phenotype. Next generation sequencing (NGS) will be employed for mutation screening of the ADPKD genes, including the duplicated PKD1, necessitating enrichment by locus specific long-range PCR (LR-PCR). Mutations and variants elsewhere in the genome will be identified employing custom-made panels of candidate genes (HaloPlex methodology) and whole exome sequencing (WES).
Aim 1 will screen the ADPKD genes to identify atypical mutations in the 7-10% of patients that are presently unresolved, and assess the role of allelic combinations as pathogenic events, especially causing EO disease.
Aim 2 will analyze a large, typical ADPKD population and ones with the vascular and sPLD phenotype to determine the full role that ADPKD genic and allelic effects play in accounting for phenotypic variability.
Aim 3 will screen loci beyond the ADPKD genes, including the whole exome, for novel causative genes resulting in an ADPKD-like phenotype.
Aim 4 will analyze the whole exome for modifying factors that cause EO disease and clinically significant vascular and hepatic complications.
The final aim will test the significance of putative pathogenic ADPKD alleles in vivo, analyzing the mechanisms of pathogenesis and optimizing mouse models for preclinical testing. Overall these studies will better explain the genetic causes of ADPKD, provide insights into the pathogenesis, possibly revealing novel therapeutic targets, optimize models for preclinical testing, be of diagnostic and prognostic value, and identify populations suitable for clinical trials and that will gain most fro disease-specific therapeutics which will be available soon.

Public Health Relevance

Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited kidney disease in which the majority of affected individuals develop renal failure, requiring dialysis or renal transplant during their adult life. Many different mutations t two different genes are known to cause the disease and have correlations between mutations and the severity and presentations of the disease in the patient population. Genetic variants in other genes will also be sought as novel causes of ADPKD or modifiers of the disease course. These studies will help understand the causes of the disease, suggesting new treatments, be of diagnostic and prognostic value, and identify a population that will gain most from treatment.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-DKUS-N (04))
Program Officer
Rasooly, Rebekah S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Cornec-Le Gall, Emilie; Olson, Rory J; Besse, Whitney et al. (2018) Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet 102:832-844
Cornec-Le Gall, Emilie; Torres, Vicente E; Harris, Peter C (2018) Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases. J Am Soc Nephrol 29:13-23
Braun, William E; Abebe, Kaleab Z; Brosnahan, Godela et al. (2018) ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. Am J Kidney Dis 71:294-296
Cornec-Le Gall, Emilie; Chebib, Fouad T; Madsen, Charles D et al. (2018) The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. Am J Kidney Dis 72:302-308
Iliuta, Ioan-Andrei; Kalatharan, Vinusha; Wang, Kairong et al. (2017) Polycystic Kidney Disease without an Apparent Family History. J Am Soc Nephrol 28:2768-2776
Chebib, Fouad T; Hogan, Marie C; El-Zoghby, Ziad M et al. (2017) Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies. Kidney Int Rep 2:913-923
Hajarnis, Sachin; Lakhia, Ronak; Yheskel, Matanel et al. (2017) microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat Commun 8:14395
Chebib, Fouad T; Jung, Yeonsoon; Heyer, Christina M et al. (2016) Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 31:952-60
Warner, Gina; Hein, Kyaw Zaw; Nin, Veronica et al. (2016) Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J Am Soc Nephrol 27:1437-47
Kline, Timothy L; Irazabal, Maria V; Ebrahimi, Behzad et al. (2016) Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease. Magn Reson Med 75:1466-73

Showing the most recent 10 out of 59 publications